细胞外基质锚定局部给药细胞因子安全增强全身癌症免疫治疗

N. Momin
{"title":"细胞外基质锚定局部给药细胞因子安全增强全身癌症免疫治疗","authors":"N. Momin","doi":"10.1158/2326-6074.CRICIMTEATIAACR18-A206","DOIUrl":null,"url":null,"abstract":"Cytokines coordinate essential mechanisms required for an antitumor response. As a result, they robustly synergize with other immunotherapies. Unfortunately, the clinical use and approval of cytokines is frequently plagued by dose-limiting toxicities. Improving the therapeutic index of cytokines can be achieved by better localizing their effects to the tumor and away from healthy tissue. Recent efforts have shown that local injections of immunomodulatory agents at or around a tumor lesion improve the efficacy and reduce the systemic exposure of these agents. However, even when administered directly into a tumor, cytokines exhibit rapid tumor clearance and limited intratumoral retention, thus doing little to address issues of toxicity and efficacy. Here we demonstrate that extracellular matrix (ECM) anchoring of intratumorally administered cytokines is a facile strategy to retain and confine these agents in the tumor. Although the ECM is an abundant component of both tumors and healthy tissue alike, intratumoral administration obviates the need to target a tumor-specific antigen. Instead, the abundance of matrix lends itself to being an effective and general target for localization across all solid tumors. ECM-anchoring of cytokines via fusion to a matrix-binding protein significantly improves their therapeutic index. Additionally, the combination of ECM-anchored cytokines with a systemic immunotherapy (e.g., a tumor-targeting antibody, checkpoint blockade, a cancer vaccine, or CAR-T-cell therapy) enhances overall survival in syngeneic tumor models compared to combination treatments using unanchored cytokines. Cytokines that are actively retained in the tumor can safely and significantly potentiate systemic immunotherapy. Given the abundant expression of ECM across different cancers, matrix-anchoring of cytokines embodies a tumor-agnostic strategy that can readily be combined with other immunotherapeutic modalities. Citation Format: Noor Momin. Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A206.","PeriodicalId":170885,"journal":{"name":"Regulating T-cells and Their Response to Cancer","volume":"210 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract A206: Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy\",\"authors\":\"N. Momin\",\"doi\":\"10.1158/2326-6074.CRICIMTEATIAACR18-A206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cytokines coordinate essential mechanisms required for an antitumor response. As a result, they robustly synergize with other immunotherapies. Unfortunately, the clinical use and approval of cytokines is frequently plagued by dose-limiting toxicities. Improving the therapeutic index of cytokines can be achieved by better localizing their effects to the tumor and away from healthy tissue. Recent efforts have shown that local injections of immunomodulatory agents at or around a tumor lesion improve the efficacy and reduce the systemic exposure of these agents. However, even when administered directly into a tumor, cytokines exhibit rapid tumor clearance and limited intratumoral retention, thus doing little to address issues of toxicity and efficacy. Here we demonstrate that extracellular matrix (ECM) anchoring of intratumorally administered cytokines is a facile strategy to retain and confine these agents in the tumor. Although the ECM is an abundant component of both tumors and healthy tissue alike, intratumoral administration obviates the need to target a tumor-specific antigen. Instead, the abundance of matrix lends itself to being an effective and general target for localization across all solid tumors. ECM-anchoring of cytokines via fusion to a matrix-binding protein significantly improves their therapeutic index. Additionally, the combination of ECM-anchored cytokines with a systemic immunotherapy (e.g., a tumor-targeting antibody, checkpoint blockade, a cancer vaccine, or CAR-T-cell therapy) enhances overall survival in syngeneic tumor models compared to combination treatments using unanchored cytokines. Cytokines that are actively retained in the tumor can safely and significantly potentiate systemic immunotherapy. Given the abundant expression of ECM across different cancers, matrix-anchoring of cytokines embodies a tumor-agnostic strategy that can readily be combined with other immunotherapeutic modalities. Citation Format: Noor Momin. Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A206.\",\"PeriodicalId\":170885,\"journal\":{\"name\":\"Regulating T-cells and Their Response to Cancer\",\"volume\":\"210 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regulating T-cells and Their Response to Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A206\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regulating T-cells and Their Response to Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

细胞因子协调抗肿瘤反应所需的基本机制。因此,它们与其他免疫疗法有很强的协同作用。不幸的是,细胞因子的临床使用和批准经常受到剂量限制毒性的困扰。提高细胞因子的治疗指数可以通过更好地将其作用定位到肿瘤和远离健康组织来实现。最近的研究表明,在肿瘤病灶处或周围局部注射免疫调节剂可提高疗效并减少这些调节剂的全身暴露。然而,即使直接给药到肿瘤中,细胞因子也表现出快速的肿瘤清除和有限的瘤内滞留,因此对解决毒性和疗效问题几乎没有帮助。在这里,我们证明细胞外基质(ECM)锚定瘤内给药细胞因子是一种简单的策略,以保留和限制这些药物在肿瘤中。尽管ECM在肿瘤和健康组织中都是一个丰富的成分,但肿瘤内给药避免了靶向肿瘤特异性抗原的需要。相反,丰富的基质使其成为所有实体瘤定位的有效和通用靶标。细胞因子通过与基质结合蛋白的融合在ecm上锚定,显著提高了它们的治疗指数。此外,与使用非锚定细胞因子的联合治疗相比,ecm锚定细胞因子与全身免疫治疗(例如,肿瘤靶向抗体、检查点阻断、癌症疫苗或car -t细胞治疗)的联合治疗可提高同基因肿瘤模型的总生存率。活跃保留在肿瘤中的细胞因子可以安全且显著地增强全身免疫治疗。考虑到ECM在不同癌症中的丰富表达,细胞因子的基质锚定体现了一种肿瘤不可知策略,可以很容易地与其他免疫治疗方式相结合。引文格式:Noor Momin。细胞外基质锚定局部给药细胞因子安全增强全身癌症免疫治疗[摘要]。第四届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议:将科学转化为生存;2018年9月30日至10月3日;纽约,纽约。费城(PA): AACR;癌症免疫学杂志,2019;7(2增刊):摘要nr A206。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abstract A206: Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy
Cytokines coordinate essential mechanisms required for an antitumor response. As a result, they robustly synergize with other immunotherapies. Unfortunately, the clinical use and approval of cytokines is frequently plagued by dose-limiting toxicities. Improving the therapeutic index of cytokines can be achieved by better localizing their effects to the tumor and away from healthy tissue. Recent efforts have shown that local injections of immunomodulatory agents at or around a tumor lesion improve the efficacy and reduce the systemic exposure of these agents. However, even when administered directly into a tumor, cytokines exhibit rapid tumor clearance and limited intratumoral retention, thus doing little to address issues of toxicity and efficacy. Here we demonstrate that extracellular matrix (ECM) anchoring of intratumorally administered cytokines is a facile strategy to retain and confine these agents in the tumor. Although the ECM is an abundant component of both tumors and healthy tissue alike, intratumoral administration obviates the need to target a tumor-specific antigen. Instead, the abundance of matrix lends itself to being an effective and general target for localization across all solid tumors. ECM-anchoring of cytokines via fusion to a matrix-binding protein significantly improves their therapeutic index. Additionally, the combination of ECM-anchored cytokines with a systemic immunotherapy (e.g., a tumor-targeting antibody, checkpoint blockade, a cancer vaccine, or CAR-T-cell therapy) enhances overall survival in syngeneic tumor models compared to combination treatments using unanchored cytokines. Cytokines that are actively retained in the tumor can safely and significantly potentiate systemic immunotherapy. Given the abundant expression of ECM across different cancers, matrix-anchoring of cytokines embodies a tumor-agnostic strategy that can readily be combined with other immunotherapeutic modalities. Citation Format: Noor Momin. Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A206.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信